The role of miRNAs as biomarkers in prostate cancer

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, 136, E359, 10.1002/ijc.29210 Kretschmer, 2017, Biomarkers in prostate cancer – current clinical utility and future perspectives, Crit. Rev. Oncol. Hematol., 120, 180, 10.1016/j.critrevonc.2017.11.007 Sanguedolce, 2016, Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review, Clin. Genitourin. Cancer, 14, 117, 10.1016/j.clgc.2015.12.001 McKiernan, 2016, A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy, JAMA Oncol., 2, 882, 10.1001/jamaoncol.2016.0097 Meiri, 2012, A second-generation microRNA-based assay for diagnosing tumor tissue origin, Oncologist, 17, 801, 10.1634/theoncologist.2011-0466 Terada, 2017, Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications, Ther. Adv. Med. Oncol., 9, 565, 10.1177/1758834017719215 Porzycki, 2018, Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition, Int. Urol. Nephrol., 50, 1619, 10.1007/s11255-018-1938-2 Brase, 2011, Circulating miRNAs are correlated with tumor progression in prostate cancer, Int. J. Cancer, 128, 608, 10.1002/ijc.25376 Shi, 2018, A five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data, Sci. Rep., 8, 7638, 10.1038/s41598-018-22493-5 Ortiz-Quintero, 2016, Cell-free microRNAs in blood and other body fluids, as cancer biomarkers, Cell Prolif., 49, 281, 10.1111/cpr.12262 Fu, 2018, A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy, Sci. Rep., 8, 7933, 10.1038/s41598-018-26374-9 Shalaby, 2014, MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons, Int. J. Mol. Sci., 15, 21554, 10.3390/ijms151121554 Long, 2018, Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets, Cancer Lett., 428, 90, 10.1016/j.canlet.2018.04.016 Lili, 2018, Time-course analysis of microRNA-induced mesenchymal-to-epithelial transition underscores the complexity of the underlying molecular processes, Cancer Lett., 428, 184, 10.1016/j.canlet.2018.05.001 Hosseinahli, 2018, Treating cancer with microRNA replacement therapy: a literature review, J. Cell. Physiol., 233, 5574, 10.1002/jcp.26514 Filella, 2017, miRNAs as novel biomarkers in the management of prostate cancer, Clin. Chem. Lab. Med. (CCLM), 55, 715, 10.1515/cclm-2015-1073 Zhou, 2014, Androgens and androgen receptor signaling in prostate tumorigenesis, J. Mol. Endocrinol., 54, R15, 10.1530/JME-14-0203 Massillo, 2017, Implications of microRNA dysregulation in the development of prostate cancer, Reproduction, 154, R81, 10.1530/REP-17-0322 Jalava, 2012, Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer, Oncogene, 31, 4460, 10.1038/onc.2011.624 Yang, 2017, miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study, Asian Pac. J. Trop. Med., 10, 87, 10.1016/j.apjtm.2016.09.011 Dong, 2015, IL-6 inhibits the targeted modulation of PDCD4 by miR-21 in prostate cancer, PLoS One, 10, 10.1371/journal.pone.0134366 Bonci, 2008, The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities, Nat. Med., 14, 1271, 10.1038/nm.1880 Schaefer, 2010, Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma, Int. J. Cancer, 126, 1166 Szczyrba, 2010, The MicroRNA profile of prostate carcinoma obtained by deep sequencing, Mol. Cancer Res., 8, 529, 10.1158/1541-7786.MCR-09-0443 Dong, 2010, MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2, PLoS One, 5, 10.1371/journal.pone.0010147 Shi, 2011, miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes, Prostate, 71, 538, 10.1002/pros.21270 Das, 2019, The basics of epithelial–mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective, J. Cell. Physiol., jcp.28160 Gregory, 2008, The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1, Nat. Cell Biol., 10, 593, 10.1038/ncb1722 Kalogirou, 2013, MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer, Int. J. Mol. Sci., 14, 21414, 10.3390/ijms141121414 Nguyen, 2013, Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer, Prostate, 73, 346, 10.1002/pros.22572 Selth, 2017, A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer, Oncogene, 36, 24, 10.1038/onc.2016.185 Zhang, 2018, Cancer stem cells: regulation programs, immunological properties and immunotherapy, Semin. Cancer Biol., 52, 94, 10.1016/j.semcancer.2018.05.001 Liu, 2011, The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, Nat. Med., 17, 211, 10.1038/nm.2284 Huang, 2012, miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells, Oncol. Rep., 28, 1831, 10.3892/or.2012.2015 Nadiminty, 2012, MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells, J. Biol. Chem., 287, 1527, 10.1074/jbc.M111.278705 Li, 2018, The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1, J. Exp. Clin. Cancer Res.: CR, 37, 219, 10.1186/s13046-018-0895-z Liu, 2013, MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms, Oncogene, 32, 296, 10.1038/onc.2012.58 Lynch, 2016, miR-24 regulates CDKN1B/p27 expression in prostate cancer, Prostate, 76, 637, 10.1002/pros.23156 Qin, 2010, miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells, PLoS One, 5, e9429, 10.1371/journal.pone.0009429 Fu, 2014, miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis, Oncogene, 33, 4296, 10.1038/onc.2013.385 Lin, 2013, Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression, Cancer Res., 73, 1232, 10.1158/0008-5472.CAN-12-2968 Chakravarthi, 2018, miR-34a regulates expression of the Stathmin-1 oncoprotein and prostate cancer progression, Mol. Cancer Res., 16, 1125, 10.1158/1541-7786.MCR-17-0230 Majid, 2013, miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways, Clin. Cancer Res., 19, 73, 10.1158/1078-0432.CCR-12-2952 Yu, 2014, miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells, Med. Oncol. (Northwood, London, England), 31, 910, 10.1007/s12032-014-0910-y Xu, 2016, miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1, Tumour Biol., 37, 12023, 10.1007/s13277-016-5058-2 Arai, 2018, Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC, Cancer Med., 7, 1988, 10.1002/cam4.1455 Sun, 2011, miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation, Cancer Res., 71, 1313, 10.1158/0008-5472.CAN-10-1031 Wu, 2015, microRNA‑99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer, Mol. Med. Rep., 11, 1469, 10.3892/mmr.2014.2792 Shi, 2013, Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells, Oncogene, 32, 4130, 10.1038/onc.2012.425 Hua, 2018, MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9, Oncol. Lett., 15, 9051 Patron, 2012, MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis, PLoS One, 7, 10.1371/journal.pone.0035345 Xiao, 2012, miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein, Prostate, 72, 1514, 10.1002/pros.22501 Liu, 2017, MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes, Nat. Commun., 8, 14270, 10.1038/ncomms14270 Ren, 2014, Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells, Cell Tissue Res., 358, 763, 10.1007/s00441-014-2001-y Larne, 2015, miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis, Carcinogenesis, 36, 858, 10.1093/carcin/bgv063 Yao, 2016, Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway, Biochem. Biophys. Res. Commun., 474, 213, 10.1016/j.bbrc.2016.04.107 Jiang, 2016, MiR-185 attenuates androgen receptor function in prostate cancer indirectly by targeting bromodomain containing 8 isoform 2, an androgen receptor co-activator, Mol. Cell. Endocrinol., 427, 13, 10.1016/j.mce.2016.02.023 Li, 2013, MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells, PLoS One, 8 Kong, 2009, miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells, Stem Cells (Dayton, Ohio), 27, 1712, 10.1002/stem.101 Chen, 2018, MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance, Eur. Rev. Med. Pharmacol. Sci., 22, 3734 Xiang, 2015, MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer, J. Exp. Clin. Cancer Res.: CR, 34, 8, 10.1186/s13046-015-0125-x Wang, 2013, miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth, Asian J. Androl., 15, 735, 10.1038/aja.2013.80 Verdoodt, 2013, MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer, Int. J. Oncol., 43, 307, 10.3892/ijo.2013.1915 Gandellini, 2009, miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon, Cancer Res., 69, 2287, 10.1158/0008-5472.CAN-08-2894 Galardi, 2007, miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1, J. Biol. Chem., 282, 23716, 10.1074/jbc.M701805200 Hsieh, 2013, MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway, Carcinogenesis, 34, 530, 10.1093/carcin/bgs371 Szczyrba, 2011, Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma, Mol. Cancer Res.: MCR, 9, 791, 10.1158/1541-7786.MCR-10-0573 Josson, 2015, Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis, Oncogene, 34, 2690, 10.1038/onc.2014.212 Noonan, 2009, miR-449a targets HDAC-1 and induces growth arrest in prostate cancer, Oncogene, 28, 1714, 10.1038/onc.2009.19 Rajendiran, 2014, MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1, Mol. Cancer, 13, 250, 10.1186/1476-4598-13-250 Wach, 2012, MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening, Int. J. Cancer, 130, 611, 10.1002/ijc.26064 Das, 2016, miR-1207-3p is a novel prognostic biomarker of prostate cancer, Transl. Oncol., 9, 236, 10.1016/j.tranon.2016.04.005 Karatas, 2014, miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer, PLoS One, 9, 10.1371/journal.pone.0098675 Wei, 2017, MiR-1, a potential predictive biomarker for recurrence in prostate cancer after radical prostatectomy, Am. J. Med. Sci., 353, 315, 10.1016/j.amjms.2017.01.006 Ling, 2014, MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer, Mol. Biol. Rep., 41, 2779, 10.1007/s11033-014-3132-7 Guan, 2016, Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy, Prostate, 76, 986, 10.1002/pros.23187 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. U. S. A., 105, 10513, 10.1073/pnas.0804549105 Gao, 2016, Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer, Neoplasma, 63, 623, 10.4149/neo_2016_417 Kachakova, 2015, Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer, DNA Cell Biol., 34, 189, 10.1089/dna.2014.2663 Pang, 2016, MiR-139-5p is increased in the peripheral blood of patients with prostate cancer, Cell. Physiol. Biochem., 39, 1111, 10.1159/000447819 Lieb, 2018, Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients, Oncotarget, 9, 10402, 10.18632/oncotarget.23781 Alhasan, 2016, Circulating microRNA signature for the diagnosis of very high-risk prostate cancer, Proc. Natl. Acad. Sci. U. S. A., 113, 10655, 10.1073/pnas.1611596113 Sun, 2015, Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer, Int. J. Clin. Exp. Pathol., 8, 8394 Xu, 2015, Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer, Int. J. Clin. Exp. Pathol., 8, 14335 Cai, 2018, miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression, Oncol. Rep., 39, 1658 Al-Qatati, 2017, Plasma microRNA signature is associated with risk stratification in prostate cancer patients, Int. J. Cancer, 141, 1231, 10.1002/ijc.30815 Balacescu, 2017, Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: are we there yet?, Wiley Interdiscip. Rev. RNA, 8, e1438, 10.1002/wrna.1438 Wu, 2017, Urinary biomarkers in prostate cancer detection and monitoring progression, Crit. Rev. Oncol. Hematol., 118, 15, 10.1016/j.critrevonc.2017.08.002 Foj, 2017, Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis, Prostate, 77, 573, 10.1002/pros.23295 Haj-Ahmad, 2014, Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients, J. Cancer, 5, 182, 10.7150/jca.6799 Fredsøe, 2017, Diagnostic and prognostic MicroRNA biomarkers for prostate cancer in cell-free urine, Eur. Urol. Focus, 4, 825, 10.1016/j.euf.2017.02.018 Salido-Guadarrama, 2016, Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone, Mol. Med. Rep., 13, 4549, 10.3892/mmr.2016.5095 Matlaga, 2003, Prostate biopsy: indications and technique, J. Urol., 169, 12, 10.1016/S0022-5347(05)64024-4 Iscaife, 2018, Treating metastatic prostate cancer with microRNA-145, Apoptosis, 23, 388, 10.1007/s10495-018-1461-z Matin, 2016, MicroRNA theranostics in prostate cancer precision medicine, Clin. Chem., 62, 1318, 10.1373/clinchem.2015.242800 Gu, 2016, Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1, Cancer Med., 5, 1174, 10.1002/cam4.664 Wang, 2016, MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1, Eur. Rev. Med. Pharmacol. Sci., 20, 92 Zhang, 2015, Insights into chemoresistance of prostate cancer, Int. J. Biol. Sci., 11, 1160, 10.7150/ijbs.11439 Chen, 2018, MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1, World J. Urol., 36, 357, 10.1007/s00345-017-2143-0 Fujita, 2015, miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells, Prostate, 75, 1568, 10.1002/pros.23031 Lin, 2018, MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer, Sci. Rep., 8, 7820, 10.1038/s41598-018-26050-y Chen, 2018, HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9, Ther. Adv. Med. Oncol., 10, 10.1177/1758835918783132 Caby, 2005, Exosomal-like vesicles are present in human blood plasma, Int. Immunol., 17, 879, 10.1093/intimm/dxh267 Pisitkun, 2004, Identification and proteomic profiling of exosomes in human urine, Proc. Natl. Acad. Sci. U. S. A., 101, 13368, 10.1073/pnas.0403453101 Aalberts, 2012, Identification of distinct populations of prostasomes that differentially express prostate stem cell antigen, annexin A1, and GLIPR2 in humans, Biol. Reprod., 86, 82, 10.1095/biolreprod.111.095760 Ogawa, 2011, Proteomic analysis of two types of exosomes in human whole saliva, Biol. Pharm. Bull., 34, 13, 10.1248/bpb.34.13 Vojtech, 2014, Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions, Nucleic Acids Res., 42, 7290, 10.1093/nar/gku347 Huang, 2013, Characterization of human plasma-derived exosomal RNAs by deep sequencing, BMC Genom., 14, 319, 10.1186/1471-2164-14-319 Tran, 2016, Cancer exosomes as miRNA factories, Trends Cancer, 2, 329, 10.1016/j.trecan.2016.05.008 Goldie, 2014, Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons, Nucleic Acids Res., 42, 9195, 10.1093/nar/gku594 Anfossi, 2018, Clinical utility of circulating non-coding RNAs – an update, Nat. Rev. Clin. Oncol., 15, 541, 10.1038/s41571-018-0035-x Valentino, 2017, Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer, Clin. Transl. Oncol., 19, 651, 10.1007/s12094-016-1599-5 Gholizadeh, 2017, Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles: current status and future directions, Biosens. Bioelectron., 91, 588, 10.1016/j.bios.2016.12.062 Koritzinsky, 2017, Quantification of exosomes, J. Cell. Physiol., 232, 1587, 10.1002/jcp.25387 Hessvik, 2013, Exosomal miRNAs as biomarkers for prostate cancer, Front. Genet., 4, 36, 10.3389/fgene.2013.00036 Huang, 2013, Extracellular microRNAs in urologic malignancies: chances and challenges, Int. J. Mol. Sci., 14, 14785, 10.3390/ijms140714785 Bryant, 2012, Changes in circulating microRNA levels associated with prostate cancer, Br. J. Cancer, 106, 768, 10.1038/bjc.2011.595 Li, 2016, Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients, OncoTargets Ther., 9, 139 Bhagirath, 2018, microRNA-1246 is an exosomal biomarker for aggressive prostate cancer, Cancer Res., 78, 1833, 10.1158/0008-5472.CAN-17-2069 Huang, 2015, Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer, Eur. Urol., 67, 33, 10.1016/j.eururo.2014.07.035 Bryzgunova, 2016, Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients, PLoS One, 11, 10.1371/journal.pone.0157566 Samsonov, 2016, Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic, Prostate, 76, 68, 10.1002/pros.23101 Welch, 2017, Effect of prolonged freezing of semen on exosome recovery and biologic activity, Sci. Rep., 7, 45034, 10.1038/srep45034 Ling, 2016, MicroRNAs in testicular cancer diagnosis and prognosis, Urol. Clin. N. Am., 43, 127, 10.1016/j.ucl.2015.08.013 Saari, 2015, Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells, J. Control. Release, 220, 727, 10.1016/j.jconrel.2015.09.031 Chen, 2011, Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs, J. Transl. Med., 9, 47, 10.1186/1479-5876-9-47 Fareh, 2017, Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth, Cell Death Dis., 8, e2713, 10.1038/cddis.2017.117 Luan, 2017, Engineering exosomes as refined biological nanoplatforms for drug delivery, Acta Pharmacol. Sin., 38, 754, 10.1038/aps.2017.12 Ohno, 2013, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells, Mol. Ther., 21, 185, 10.1038/mt.2012.180 Hafner, 2008, Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing, Methods (San Diego, Calif.), 44, 3, 10.1016/j.ymeth.2007.09.009 Persson, 2017, Preparation of highly multiplexed small RNA sequencing libraries, BioTechniques, 63, 57, 10.2144/000114574 Zhao, 2018, Identification of valid reference genes for mRNA and microRNA normalisation in prostate cancer cell lines, Sci. Rep., 8, 1949, 10.1038/s41598-018-19458-z Hu, 2014, Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients, Int. J. Cancer, 135, 1187, 10.1002/ijc.28757 Vandesompele, 2002, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol., 3, 10.1186/gb-2002-3-7-research0034 Moshiri, 2018, Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma, Oncotarget, 9, 15350, 10.18632/oncotarget.24601 Guan, 2018, Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data, Gene, 647, 205, 10.1016/j.gene.2017.12.031 Guelfi, 2018, Next generation sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research, Sci. Rep., 8, 7111, 10.1038/s41598-018-24236-y Marzi, 2016, Optimization and standardization of circulating MicroRNA detection for clinical application: the miR-test case, Clin. Chem., 62, 743, 10.1373/clinchem.2015.251942 Kappel, 2017, miRNA assays in the clinical laboratory: workflow, detection technologies and automation aspects, Clin. Chem. Lab. Med., 55, 636, 10.1515/cclm-2016-0467 Witwer, 2015, Circulating microRNA biomarker studies: pitfalls and potential solutions, Clin. Chem., 61, 56, 10.1373/clinchem.2014.221341 Mazumder, 2019, Liquid biopsy: miRNA as a potential biomarker in oral cancer, Cancer Epidemiol., 58, 137, 10.1016/j.canep.2018.12.008